SCHEMBL3015201

SCHEMBL3015201

COc1ccc(S(=O)(=O)C2CCN(c3nc(Cc4ccc(Cl)cc4Cl)cs3)CC2)c(OC)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.37
LMNA P02545 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
F2RL3 Q96RI0 4/20 0.36
F2 P00734 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
RAB9A P51151 1/20 0.35
TP53 P04637 2/20 0.35
CYP19A1 P11511 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
HTR6 P50406 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
USP2 O75604 1/20 0.34
TSHR P16473 1/20 0.34
FPR2 P25090 2/20 0.34
PROKR1 Q8TCW9 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017810 0.93 ALDH1A1 (0.40) MAPTLMNASMN1; SMN2RAB9ATP53
SCHEMBL3013303 0.93 MAPT (0.37) MAPTLMNATDP1F2RL3F2
SCHEMBL3013075 0.91 MAPT (0.40) MAPTLMNATDP1F2RL3SMN1; SMN2
SCHEMBL3016184 0.90 SMN1; SMN2 (0.37) MAPTLMNATDP1F2RL3F2
SCHEMBL3021636 0.90 SMN1; SMN2 (0.37) MAPTLMNATDP1F2RL3F2
SCHEMBL3014404 0.90 MAPT (0.39) MAPTLMNATDP1F2RL3F2
SCHEMBL3002902 0.90 TP53 (0.41) MAPTLMNATDP1SMN1; SMN2RAB9A
SCHEMBL3011425 0.89 MAPT (0.39) MAPTLMNATDP1F2RL3F2
SCHEMBL3014972 0.89 MAPT (0.38) MAPTLMNATDP1F2RL3F2
SCHEMBL3019361 0.89 RAB9A (0.39) MAPTLMNATDP1F2RL3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885LMNA 80/4885TDP1 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.